- Companies
- Mycodern
Mycodern Valuation Multiples
Mycodern is valued at $14M as of August 2026. In the last fiscal year, Mycodern EBITDA was $50K.
Mycodern Overview
About Mycodern
Mycodern SA is committed to providing the highest quality functional food and innovative dietary supplement products.
Founded
1999
HQ
Employees
7
Website
Financials (Last FY)
EV
$14M
Valuation Multiples
Start free trialMycodern Financials
Mycodern reported last fiscal year revenue of ($3K) and EBITDA of $50K.
In the same fiscal year, Mycodern generated $3K in gross profit, $50K in EBITDA, and had net loss of ($65K).
Mycodern P&L
In the most recent fiscal year, Mycodern reported revenue of ($3K) and EBITDA of $50K.
Mycodern is unprofitable as of last fiscal year, with gross margin of (83%), EBITDA margin of (1549%), and net margin of 2033%.
Financial data powered by Morningstar, Inc.
Mycodern Stock Performance
Mycodern has current market cap of $14M, and enterprise value of $14M.
Market Cap Evolution
Mycodern's stock price is $0.21.
Mycodern share price increased by 18.1% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $14M | 0.0% | - | 1.3% | 18.1% | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMycodern Valuation Multiples
Mycodern trades at (4301.7x) EV/Revenue multiple, and 277.7x EV/EBITDA.
Mycodern Financial Valuation Multiples
As of October 16, 2026, Mycodern has market cap of $14M and EV of $14M.
Mycodern has a P/E ratio of (213.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mycodern Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Mycodern Margins & Growth Rates
In the most recent fiscal year, Mycodern reported gross margin of (83%), EBITDA margin of (1549%), and net margin of 2033%.
Mycodern Margins
Mycodern Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Mycodern Operational KPIs
Mycodern's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Mycodern Competitors
Mycodern competitors include Simris Group, 7FIT, Hemp & Health, Bio Essence, Optimi Health, Enorama Pharma, Nuchev, Pharmena, Valbiotis and Aqua Bio Technology.
Most Mycodern public comparables operate across Nutraceuticals & Cosmeceuticals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $162K | ($2M) | 95.3x | - | (9.9x) | - | |||
| $9M | $978K | 1.3x | - | 12.0x | - | |||
| $54K | ($370K) | 187.9x | - | (27.2x) | - | |||
| $2M | $899K | 10.2x | - | 21.5x | - | |||
| $300K | ($2M) | 42.5x | 26.7x | (8.1x) | - | |||
| $274K | ($7M) | 31.5x | - | (1.2x) | - | |||
| $18M | ($5M) | 0.6x | 0.6x | (2.2x) | - | |||
| $404K | ($808K) | 17.8x | - | (8.9x) | - | |||
This data is available for Pro users. Sign up to see all Mycodern competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mycodern
| When was Mycodern founded? | Mycodern was founded in 1999. |
| Where is Mycodern headquartered? | Mycodern is headquartered in Poland. |
| How many employees does Mycodern have? | As of today, Mycodern has over 7 employees. |
| Is Mycodern publicly listed? | Yes, Mycodern is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Mycodern? | Mycodern trades under MCD ticker. |
| When did Mycodern go public? | Mycodern went public in 2023. |
| Who are competitors of Mycodern? | Mycodern main competitors include Simris Group, 7FIT, Hemp & Health, Bio Essence, Optimi Health, Enorama Pharma, Nuchev, Pharmena, Valbiotis, Aqua Bio Technology. |
| What is the current market cap of Mycodern? | Mycodern's current market cap is $14M. |
| What is the current revenue of Mycodern? | Mycodern's last fiscal year revenue is ($3K). |
| What is the current EV/Revenue multiple of Mycodern? | Current revenue multiple of Mycodern is (4301.7x). |
| Is Mycodern profitable? | No, Mycodern is not profitable. |
| How many companies Mycodern has acquired to date? | Mycodern hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Mycodern has invested to date? | Mycodern hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Mycodern
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




